Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
P/S ratio for Advaxis, Inc. (ADXS)
P/S ratio as of 2023: 307.38
According to Advaxis, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 307.38. At the end of 2022 the company had a P/S ratio of 13.53.
P/S ratio history for Advaxis, Inc. from 2002 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 307.38 |
| 2022 | 13.53 |
| 2021 | 20.19 |
| 2020 | 81.50 |
| 2019 | 2.06 |
| 2018 | 385.23 |
| 2017 | 925.51 |
| 2016 | 5793.02 |
| 2015 | 0.00 |
| 2014 | 4395.72 |
| 2013 | 0.00 |
| 2012 | 0.00 |
| 2011 | 0.00 |
| 2010 | 3717.07 |
| 2009 | 40866.69 |
| 2008 | 2751.13 |
| 2007 | 5259.62 |
| 2006 | 1409.76 |
| 2005 | 1333.66 |
| 2004 | 34955.99 |
| 2003 | 0.00 |
| 2002 | 0.00 |